Tiny Cup Attached to Eye Improves Drug Delivery For Retinal Diseases
LOS ANGELES, Aug. 7 /PRNewswire-USNewswire/ -- A new drug
delivery system that uses a tiny silicone cup filled with any drug and sealed to the outer surface (episclera) of the eyeball may offer a more effective method for the sustained
delivery of medicines for retinal and vitreous disea...
Iontophoretic Drug Delivery System (IDDS) Containing Lidocaine and Epinephrine is Effective in Reducing Pain Associated With Insertion of an Intravenous Catheter in a Phase 2 Clinical Trial
SEATTLE, July 9 /PRNewswire/ -- Dharma Therapeutics, Inc., ("Dharma") Seattle, WA (a subsidiary of the Transcu Group Limited, a company listed on the Singapore Exchange Limited) announced that its improved active transdermal
delivery technology, which administers lidocaine and epinephrine through ...
Cardiogenesis Announces Presentation of its PHOENIX(R) Combination TMR Plus Stem Cell Delivery System at the International Society of Minimally Invasive Cardiothoracic Surgeons (ISMICS) Annual Meeting
IRVINE, Calif., June 4 /PRNewswire-FirstCall/ -- Cardiogenesis Corporation (Pink Sheets: CGCP) the market leader in laser transmyocardial revascularization (TMR) for the treatment of chronic cardiac ischemia, announces that Dr. Naresh Trehan of New Delhi will be presenting his clinical results of ...
New Study Suggests Rx Estrogen Delivery Through the Skin May Show Safety Benefits as Opposed to Oral Delivery
NEW YORK, March 31 /PRNewswire/ -- Transdermal
delivery of estrogen therapy available by prescription "seems not to alter" the risk of venous thromboembolism (VTE), or blood clotting, in postmenopausal patients when compared to oral delivery, a new study suggests. The study was conducted by res...
Michael J. Fox Foundation Awards $2.1 Million to Improve Drug Delivery in Parkinson's Disease
NEW YORK, March 27 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation announced that it has awarded approximately $2.1 million total to seven research teams working to improve drug
delivery for Parkinson's disease.
The funding was awarded under the Foundation's Improving
Delivery of Pa...
DSM Obtains Exclusive World-Wide License for Innovative Drug Delivery Technology
SAN DIEGO, March 11 /PRNewswire/ -- Royal DSM N.V., the global Life Sciences and Materials Sciences company headquartered in the Netherlands , today announces that DSM Biomedical obtained an exclusive world-wide license for a unique drug & biologic
delivery system developed by MediVas LLC,...
Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile
-
Delivery of 20,000 doses of ABthrax will bring at least $150 million in revenue to HGS -
ROCKVILLE, Md., Feb. 2 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI ) today announced that it has begun
delivery of 20,000 doses of its human monoclonal antibody drug ABthrax(TM...
Reproductive Partners Participates in New IVF Progesterone Delivery System Study
Southern California fertility center participates in a national study to explore new IVF progesterone
delivery systems replacing intramuscular injections.
LOS ANGELES, Jan. 12 /PRNewswire/ -- Reproductive Partners Medical Group a leading Southern California fertility center esteemed for the...
Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
12 Patient Trial Targets Advanced Solid Tumors, Including Lung Cancer
SAN FRANCISCO, Oct. 15 /PRNewswire/ -- Jennerex, Inc. (San Francisco,
CA and Ottawa, Canada) today announced the completion of treatment for the
first patient cohort in the Phase 1 cancer clinical trial of its targeted
poxv...
CEL-SCI Expects to Take Delivery of New Manufacturing Facility on October 8, 2008
VIENNA, Va., Sept. 16 /PRNewswire-FirstCall/ -- CEL-SCI Corporation
(Amex: CVM ) announced today that it expects to take
delivery of the new
manufacturing facility for its lead drug Multikine(R) on October 8, 2008.
This dedicated facility will produce the Multikine that will be used for
CEL-S...
Oramed Pharmaceuticals Launches GLP1-Analog Program, Based on its Proprietary Drug Delivery Platform
ORMD 0901 is Being Developed as an Oral Dosage Form of a GLP1-analog Aimed at Improving Glycemic Control in Adults With Type 2 Diabetes
JERUSALEM, Israel, September 16 /PRNewswire-FirstCall/ -- Oramed
Pharmaceuticals, Inc. (OTCBB: ORMP.OB), a developer of oral drug delivery
systems, announ...
(RED) to Launch New Way for People to Get Music in Their Lives; Weekly Delivery of Great Music Helps to Save Lives in Africa
Led by Don MacKinnon, Founder of HEAR Music
NEW YORK, June 30 /PRNewswire/ -- In the fall of 2008, (RED) will
unveil a simple, seamless way for people to receive music from artists they
love and artists they will discover through (RED). By applying the (RED)
idea to music this ne...
Phase I/II Study of Targeted Gene Delivery In Vivo - Intravenous Infusions of REXIN-G - Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Patients With Progressive Chemo-Resistant Bone and Soft Tissue Sarcoma (ASCO 2008)
SAN MARINO, Calif., May 29 /PRNewswire/ -- Epeius Biotechnologies
( http://www.epeiusbiotech.com ) announced today the results of an on-going
Phase I/II study of Rexin-G for metastatic bone and soft tissue sarcoma (J
Clin Oncol 26: 14509, 2008). Rexin-G is the first and so far only targeted
ge...
TARGETED GENE DELIVERY SIGNALS CANCER VACCINATION IN VIVO: Intravenous Infusions of Rexin-G Followed by Reximmune-C Induce Tumor Necrosis and Recruitment of Tumor Infiltrating Lymphocytes in Cancerous Lesions (ASCO 2008)
SAN MARINO, Calif., May 27 /PRNewswire/ -- Epeius Biotechnologies
( http://www.epeiusbiotech.com ) announced today that the results of a Phase
I Feasibility Study of sequential targeted gene
delivery -- using Rexin-G
followed by Reximmune-C -- for cancer vaccination will be presented at the
AS...
TARGETED GENE DELIVERY IN VIVO: Rexin-G Monotherapy Reveals Significant Biological Activity Without Toxicity in Chemo-Resistant Metastatic Breast Cancer (ASCO 2008)
SAN MARINO, Calif., May 22 /PRNewswire/ -- Epeius Biotechnologies
announced today the promising results of an on-going United States-based
Phase I/II study of Rexin-G for metastatic breast cancer that is refractory
to conventional chemotherapy (J Clin Oncol 26:14509, 2008). This clinical
trial...
Phosphagenics Reports Positive Pre-clinical Results for Targeted Delivery of Lidocaine
- Company's TPM Drug
Delivery Technology Demonstrates Substantial Increase in Lidocaine Penetration Compared to a Leading Marketed Product -
MELBOURNE, Australia, April 30 /PRNewswire-FirstCall/ -- Phosphagenics
Limited ("Phosphagenics") (ASX: POH, AIM: PSG, OTCQX: PPGNY) today
announced posi...
In Blood Vessel Stents, Innovative Materials Allow Better Control, Delivery of Gene Therapy
PHILADELPHIA, April 15 /PRNewswire-USNewswire/ -- Before gene therapy
becomes practical for treating human diseases, researchers must master the
details of safe and effective delivery. Cardiology researchers at The
Children's Hospital of Philadelphia have advanced
delivery techniques by
cre...
Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
- New Approach to Targeting the Tumor Microenvironment -
SAN DIEGO, April 15 /PRNewswire-FirstCall/ -- Halozyme Therapeutics,
Inc. (Nasdaq: HALO ), a biopharmaceutical company developing and
commercializing products targeting the extracellular matrix, today
announced new pre-clinical ...
Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
BETHESDA, Md., April 14 /PRNewswire-FirstCall/ -- Micromet, Inc.
(Nasdaq: MITI ), a biopharmaceutical company developing novel, proprietary
antibodies for the treatment of cancer, inflammation and autoimmune
diseases, presented data at the annual meeting of the American Association
for Cancer...
Study Shows Intradigm's RNAi Nanoplex Technology To Be Effective Systemic siRNA Delivery Platform for the Treatment of Various Cancer Models
Findings Support Gene-Silencing Mechanism and Demonstrate Significant Tumor Growth Inhibition Across Multiple Tumor Models in Mice
PALO ALTO, Calif., April 14 /PRNewswire/ -- Intradigm Corporation, a
leading developer of targeted, systemic RNA interference (RNAi)
therapeutics, today anno...
CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
KIRKLAND, Wash., Sept. 11 /PRNewswire-FirstCall/ -- CellCyte Genetics
Corporation (the "Company") (OTC Bulletin Board: CCYG) has entered into a
collaborative research agreement with physician scientists at the Cleveland
Clinic Foundation of Cleveland, Ohio. The goal of the collaboration is to
...
Dr. Rajeev Venkayya Joins Gates Foundation as Director of Global Health Delivery
Will oversee efforts to expand access to effective health solutions in developing countries
SEATTLE, Jan. 22 /PRNewswire/ -- The Bill & Melinda Gates Foundation
announced today that Dr. Rajeev Venkayya has joined the Global Health
Program as director of Global Health ...
Vaxiion Researchers Discover Novel Vaccine Delivery System in
Collaboration with San Diego State University
SAN DIEGO--(BUSINESS WIRE)--Mar 8, 2007 - Vaxiion Therapeutics,
Inc. today announced that its researchers, in collaboration with
San Diego State University, have discovered a 'minicell' vaccine
delivery system that has potential to protect against several
disease-causing infections.
These findings...
Calando Pharmaceuticals Publishes the First Non-Human Primate Study
on Targeted, Systemic Delivery of siRNA in National Academy of
Sciences Journal
PASADENA, Calif.--(BUSINESS WIRE)--Mar 20, 2007 - Calando
Pharmaceuticals, a leading siRNA therapeutics company and a
majority-owned subsidiary of Arrowhead Research Corporation
(NASDAQ: ARWR) announced the publication in the Proceedings of the
National Academy of Sciences (PNAS), the scientific jo...
Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on
Targeted, Systemic Delivery of siRNA
PASADENA, Calif.--(BUSINESS WIRE)--Mar 20, 2007 - Arrowhead
Research Corporation (NASDAQ:ARWR) announced today that
majority-owned subsidiary Calando Pharmaceuticals has published
results in the Proceedings of the National Academy of Sciences
(PNAS) of the first non-human primate study to use multi...
Inovio Biomedical's DNA Delivery Technology Significantly Enhances
Potency of HIV DNA Vaccine
SAN DIEGO--(BUSINESS WIRE)--Mar 26, 2007 - Inovio Biomedical Corp.
(AMEX:INO), which is focused on the development of DNA vaccines and
a novel solid tumor ablation therapy, announced today that the
Journal of Virology has published a scientific paper prepared by
Inovio's development partner, Wyeth,...
Poster on Cyclosert Drug Delivery Presented at AACR Meeting
Novel System May Provide Cancer Patients With Improved Potential to
Battle Their Disease
PASADENA, Calif., April 16, 2007 /PRNewswire/ -- Insert
Therapeutics, Inc., a majority-owned subsidiary of Arrowhead
Research Corporation announced today its novel
delivery system
called Cyclosert(TM) will be ...
Arrowhead Subsidiaries Insert & Calando Present Data on
Cyclosert Drug Delivery System at AACR Meeting
Novel Systems May Provide Cancer Patients With Improved Potential
to Battle Their Disease
PASADENA, Calif., April 16, 2007 /PRNewswire-FirstCall/ --
Arrowhead Research Corporation announced today that two of its
majority-owned subsidiaries, Insert Therapeutics Inc. and Calando
Pharmaceuticals Inc....
Calando Pharmaceuticals Announces Preclinical Efficacy and Safety
Data of Targeted, Systemic Delivery of siRNA at AACR Annual Meeting
Data Indicate Significant Anti-Tumor Effects of Targeted, Systemic
siRNA Therapeutic at Doses Significantly Lower Than the Limits of
Safe Administrations in Rodent and Non-Human Primates
PASADENA, Calif., April 16, 2007 /PRNewswire/ -- Calando
Pharmaceuticals, a leading siRNA therapeutics company ...
Baxter Presents Phase I Inhaled Insulin Study Results at
Respiratory Drug Delivery Conference
Findings Suggest Insulin Powder Produced Using Baxter's PROMAXX
Microsphere Technology was Absorbed Systemically with No Reported
Cough or Shortness of Breath
PARIS, April 20, 2007 /PRNewswire-FirstCall/ -- Baxter
Healthcare Corporation announced results of a Phase I study that
evaluated pulmonary...
CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively
Licensed to Subsidiary, RXi Pharmaceuticals, Described in
Peer-Reviewed Journal
LOS ANGELES--(BUSINESS WIRE)--Apr 23, 2007 - CytRx Corporation
(NASDAQ:CYTR) today announced that the RNA interference (RNAi)
delivery technology exclusively licensed to its majority-owned
subsidiary, RXi Pharmaceuticals Corporation (RXi), has been
published in the April 2007 issue of peer-reviewed...
Bema Fentanyl Demonstrates Substantial Transmucosal Delivery In
Absolute Bioavailability Study
MORRISVILLE, N.C.--(BUSINESS WIRE)--May 7, 2007 - BioDelivery
Sciences International, Inc. (Nasdaq:BDSI) announced the results of
a 12 subject, crossover study comparing the absorption of fentanyl
from both single and multiple BEMA(TM) Fentanyl discs, as well as
oral and intravenous doses of fentan...
Inovio: DNA delivery technology shows positive human results
Inovio Biomedical’s DNA
Delivery Technology
Significantly Enhances Potency of Gene-Based Prostate Cancer
Vaccine
Key Milestone for First-in-Man DNA Vaccine Clinical Trial Using
Inovio’s Electroporation DNA
Delivery Technology
SAN DIEGO, May 22, 2007 -- Inovio Biomedical Corp. (...
Vical's Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA
Vaccine Performance; Yields Antibody Responses Comparable to
Electroporation Without Tolerability Issues
MALAGA, Spain, May 23, 2007 /PRNewswire-FirstCall/ -- Vical
Incorporated today announced that in a recently completed animal
study, a DNA vaccine formulated with the company's patented
Vaxfectin(TM) adjuvant and delivered by needle-free injection
yielded significantly higher antibody responses tha...
Inovio Biomedical's DNA Delivery Technology Shows Safety and
Enhances Gene Expression & Tumor Responses in Interim Melanoma
Clinical Study Results
SAN DIEGO--(BUSINESS WIRE)--May 24, 2007 - Inovio Biomedical
Corporation (AMEX:INO), focused on the development of DNA-based DNA
vaccines for cancers and infectious diseases and a novel
alternative to surgery to treat localized cancers, announced today
that interim clinical trial results demonstrat...
News from the Battlefield of Metastatic Cancer: Epeius
Biotechnologies Draws the Sword of Targeted Gene Delivery (Rexin-G)
from the Stone of Chemistry and Physics
SAN MARINO, Calif., June 04, 2007 /PRNewswire/ -- (SEND2PRESS
NEWSWIRE) -- Epeius Biotechnologies Corporation today announced the
publication of a historic landmark in medical oncology and a
definitive benchmark in the emerging field of cancer gene therapy.
The first clinical report of its kind, L...
Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with
Electroporation DNA Delivery Technology and New Devices at Gene
Therapy Meeting
SAN DIEGO--(BUSINESS WIRE)--Jun 6, 2007 - Inovio Biomedical
Corporation (AMEX:INO), focused on the development of DNA vaccines
for cancers and infectious diseases and a novel alternative to
surgery to treat localized cancers, announced today the company
delivered multiple presentations on preclinic...
Vical Interim Clinical Results Demonstrate Safety and Tolerability
of Inovio Biomedical's Electroporation DNA Delivery Technology
SAN DIEGO--(BUSINESS WIRE)--Jun 7, 2007 - Inovio Biomedical
Corporation (AMEX:INO), focused on the development of DNA vaccines
for cancers and infectious diseases and a novel alternative to
surgery to treat localized cancers, announced today that the
company's partner, Vical Incorporated, presented...
PARI Pharma Presents Study Results of Sinus Delivery and Inhaled
Liposomal Ciclosporin A at European Cystic Fibrosis Conference
MUNICH, Germany, June 14, 2007 /PRNewswire/ -- PARI Pharma will
present in-vivo study results for their PARI SINUS pulsating drug
delivery system as well as lung deposition and pharmacokinetic data
of their proprietary inhaled liposomal Ciclosporin A formulation in
lung transplant patients at the ...
Next Safety, Inc.'s Innovative Drug Delivery System Will Replace
Cigarettes and Significantly Advance Pulmonary Medication Delivery
WEST JEFFERSON, N.C.--(BUSINESS WIRE)--Jun 15, 2007 - Next Safety,
Inc. has identified basic scientific mechanisms that promise to
revolutionize pulmonary drug delivery. This proprietary technology
uses a stream of purified air to deliver medications deep into the
pulmonary system. It is considered...